Definium Therapeutics, Inc. (DFTX) shares surged 49.73 percent, gaining $12.17 to $36.65 on Monday, after the company reported positive topline results from its Phase 3 Emerge study evaluating DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD).
Monday, AbbVie Inc. (ABBV) announced an agreement to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash, valuing the latter at approximately $10.9 billion. Under the agreement, the company will acquire Apogee's diverse pipeline of multiple clinical-stage candidates in development across...
InSilico Medicine Cayman TopCo (3696.HK) on Monday announced partnership with SK Biopharmaceuticals Co., Ltd. (326030.KS) to discover artificial intelligence-enabled drug candidates targeting neuroimmune disorders of the central nervous system, in a deal worth more than $2.5 billion. Under the agreement,...
Incyte Biosciences (INCY) in Japan announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
Apogee Therapeutics, Inc. (APGE) shares surged 46.72 percent, gaining $42.23 to $132.61 on Monday, after AbbVie announced a definitive agreement to acquire the biotechnology company in an all-cash transaction valued at approximately $10.9 billion.
Biopharmaceutical company AbbVie, Inc. announced Monday an agreement to acquire inflammatory and immunological drug maker Apogee Therapeutics for $135.11 per share in cash, for a total equity value of around $10.9 billion. Following the news, AbbVie shares are gaining 4 percent, while Apogee shares are surging around 47 percent.
Exelixis, Inc. (EXEL) on Monday reported final analysis results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with Roche's Tecentriq versus regorafenib in previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer. In the STELLAR-303 trial,...
Definium Therapeutics, Inc. (DFTX) on Monday reported positive topline results from its Phase 3 Emerge study evaluating a single dose of DT120 orally disintegrating tablet (ODT) in adults with major depressive disorder. The company's shares rose more than 30% in pre-market trading.
Biopharmaceutical company MapLight Therapeutics, Inc. (MPLT) announced Monday that the IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with autism spectrum disorder (ASD). IRIS (ML-004-002) is a Phase 2 study of ML-004 in ASD. The study randomized 161...
UCB (UCB.BR) announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI, demonstrating improved survival and functional outcomes in treated patients, along with acceptable tolerability. Approved by the FDA in November...
Sanofi SA (SNY) on Tuesday said the European Commission has approved Cenrifki for the treatment of secondary progressive multiple sclerosis (SPMS) in adults who have not experienced relapses in the past two years. The approval was supported by results from the Phase 3 HERCULES study, which showed...
June's FDA calendar offers plenty for investors to keep a close eye on. Among the key names are Spero Therapeutics, awaiting an FDA decision on its antibiotic for complicated urinary tract infections; Kiniksa Pharma, seeking approval for a technology transfer of the manufacturing process for Arcalyst drug substance; and Merck, pursuing the first FDA approval for its WELIREG - KEYTRUDA combination.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Retailer Target Corp. is recalling select Up & Up Baby Wipes, due to potential microbial contamination, according to the U.S. Food and Drug Administration. The recall involves Up & Up FragranceFree Baby Wipes and Up & Up Fresh Cucumber Scented Baby Wipes with various counts and UPC numbers. The impacted wipes were manufactured by a supplier, Sapro Temizlik Urunleri, and sold at Target stores...
a2 Milk Company Ltd. (ACOPF, A2M.AX), a dairy company, announced a recall of select infant milk formula, manufactured by Synlait Milk Limited and sold only in the United States, citing the presence of cereulide. The recall involves three batches of a2 Platinum USA label infant milk formula, comprising...
uniQure N.V. (QURE), a gene therapy company has launched a proposed $150 million underwritten public offering as it looks to strengthen its balance sheet and support ongoing development programs.
A new study from Binghamton University suggests that depression may affect how children pay attention to emotional facial expressions, such as happy or sad faces. Researchers also found that these patterns vary depending on whether a child has a family history of depression. During the study, scientists...
The Ebola outbreak in eastern Congo has now reached 1,003 confirmed cases, including 254 deaths, according to the Democratic Republic of the Congo's Ministry of Health. Since the outbreak was declared on May 15, about 100 people have recovered, while at least 365 patients remain hospitalized or in...
The Ebola outbreak in the Democratic Republic of Congo, known as Bundibugyo virus disease (BVD), is growing quickly. As of June 17, the World Health Organization reports 896 confirmed infections and 232 fatalities.
A new study, published in JAMA Network Open, suggests that women who are actively taking combined contraceptive pills may be more likely to experience binge eating. The study, led by researchers from Michigan State University, followed 422 women in the United States and Canada over 49 days across...
Now that Definium Therapeutics Inc. (DFTX) has reported positive results from its Phase 3 Emerge trial, greater clarity has emerged around the clinical profile and potential of its lead investigational asset, DT120 Orally Disintegrating Tablet.